COMMUNIQUÉS West-GlobeNewswire

Cara Therapeutics Announces No Modifications in Trial Size After Completion of Interim Statistical Assessment For KALM-1 Phase 3 Trial Of KORSUVA™ Injection in Hemodialysis Patients with Pruritus

02/01/2019 - 13:00

- Trial continues as planned with enrollment target of 350 patients - - Top-line data readout expected in the first half of 2019 - STAMFORD, Conn., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA [...]

Tonix Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussion

02/01/2019 - 13:00

NEW YORK, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will [...]

BioCryst Initiates Phase 1 Clinical Trial of Galidesivir

02/01/2019 - 13:00

RESEARCH TRIANGLE PARK, N.C., Jan. 02, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the dosing of the first subject in a randomized, placebo-controlled phase 1 clinical trial to [...]

Arcturus Therapeutics to Develop ARCT-810 for Treatment of Ornithine Transcarbamylase (OTC) Deficiency

02/01/2019 - 13:00

SAN DIEGO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare, liver and [...]

ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2

02/01/2019 - 13:00

LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the [...]

Holding(s) in Company

02/01/2019 - 10:40

TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the [...]

ASLAN Pharmaceuticals Completes Enrolment for Global Pivotal TreeTopp Study Ahead of Schedule

02/01/2019 - 09:48

Topline data from largest global, placebo-controlled study in second line biliary tract cancer expected in the second half of 2019 SINGAPORE, Jan. 02, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx: [...]

ObsEva SA to Participate in JP Morgan Healthcare Conference January 7-10, 2019

02/01/2019 - 07:00

Geneva, Switzerland and Boston – January 2, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious [...]

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01/01/2019 - 00:00

CAMBRIDGE, Mass., Dec. 31, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2018, that were previously [...]

Adamis Pharmaceuticals Submits New Drug Application to FDA for Its Naloxone Pre-Filled Syringe

31/12/2018 - 22:02

SAN DIEGO, Dec. 31, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for its naloxone pre [...]

U.S. Food and Drug Administration Approves Portola Pharmaceuticals’ Prior Approval Supplement for Andexxa® Generation 2 Manufacturing Process

31/12/2018 - 21:19

– Expands Patient Access to Andexxa, the First and Only Antidote for Reversal of the Factor Xa Inhibitors Rivaroxaban or Apixaban – – Full Commercial Launch to Begin January 2019 – SOUTH SAN FRANCISCO, Calif., Dec. 31, [...]

Green Growth Brands Reaffirms Commitment to Takeover Aphria Inc.

31/12/2018 - 21:04

Welcomes early expressions of interest from a growing number of frustrated Aphria shareholders who want a way out of a failed investment Offer valued at C$11.00 per Aphria share represents significant and compelling [...]

Merus annonce les résultats financiers du troisième trimestre 2018 et fait le point sur son activité

31/12/2018 - 20:45

Jalons cliniques des quatre principaux programmes Biclonics® prévus en 2019 Les liquidités devraient être suffisantes pour financer les activités du deuxième trimestre 2021 UTRECHT, Pays-Bas, 31 déc. 2018 (GLOBE [...]

Alder BioPharmaceuticals® to Present at the 37th Annual J.P. Morgan Healthcare Conference

31/12/2018 - 14:00

BOTHELL, Wash., Dec. 31, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today [...]

CLS Holdings USA, Inc. Issues Year End Review Letter

31/12/2018 - 14:00

LAS VEGAS, Dec. 31, 2018 (GLOBE NEWSWIRE) -- CLS Holdings USA, Inc. (OTCQB: CLSH) “CLS,” a diversified cannabis company operating as Cannabis Life Sciences and an integrated cannabis producer and retailer in Nevada [...]

Acasti Pharma Announces TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia Has Now Exceeded 65% Randomization, and More Than 100 Patients (>20%) Have Completed Their 6 Month Treatment Plan

31/12/2018 - 14:00

LAVAL, Québec, Dec. 31, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of [...]

Onconova to Meet Investors and Potential Partners at China Focus and the 37th Annual J.P. Morgan Healthcare Conferences in San Francisco

31/12/2018 - 13:30

NEWTOWN, Pa., Dec. 31, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary [...]

Geron Announces New Board Leadership Structure

31/12/2018 - 13:30

CEO John A. Scarlett Appointed Chairman Karin Eastham Appointed Lead Independent Director MENLO PARK, Calif., Dec. 31, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced changes to the leadership [...]

Peter D. Meldrum (1947-2018)

31/12/2018 - 13:05

Myriad Salutes the Life and Achievements of Its Co-Founder SALT LAKE CITY, Dec. 31, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) today announced that the company’s former CEO Peter Durkee Meldrum, age [...]